Solid Biosciences is merging with Sarepta-backed AavantiBio in a $215m deal while Amazon has formed a minority founder-focused $150m fund.

M&A Nasdaq-listed Duchenne muscular dystrophy therapy developer Solid Biosciences is merging with AavantiBio, a US-based gene therapeutics provider backed by genetic medicine group Sarepta Therapeutics, through a $215m cash and investment deal. Business management automation tool provider ZenBusiness has acquired Ureeka, a US-based minority founder-focused mentoring platform backed by enterprise software firm Salesforce, for an…

The rest of this content is only accessible to Global Venturing Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.